Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has worked hard but unsuccessfully to produce a single therapy, variously named Pro 140, leronlimab, and Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in terms of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be being used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as a combination therapy in the treatment of multi-drug-resistant HIV have been closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my past few shares. My 1st CytoDyn article, “CytoDyn: What To Do When It is Too Good to be able to Be True?”, set away what follows prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan presented such a highly marketing picture in the Uptick Newswire job interview which I came away with an inadequate viewpoint of the business.

Irony of irony, the bad viewpoint of mine of the company has grown steadily, although the disappointment has not been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger yet still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much storied therapy (which I shall relate to as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your therapy as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of this know-how as well as associated intellectual property coming from Progenics to CytoDyn, as well as roughly twenty five million mg of bulk drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 million) plus the very first new drug program endorsement ($5 million), and also royalty payments of five % of net sales after commercialization.

Since that time, CytoDyn’s leading nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to get a market cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous therapies and numerous indications, it’s this individual therapies as well as a “broad pipeline of indications” as it puts it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely advantageous therapy of dozens of indications.

The opening banner of its on its website (below) shows an energetic company with diverse interests albeit focused on leronlimab, several disease types, multiple publications and multiple delivering presentations.

Could all this be smoke cigarettes and mirrors? That is a question I’ve been asking myself with the really start of the interest of mine in this particular business. Judging by way of the multiples of a huge number of various commentary on listings accessible via Seeking Alpha’s CytoDyn Summary page, I am far from alone in this question.

CytoDyn is a traditional battleground, or some could say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *